About US
Contact us
-
Biogen and Eisai terminate trial of Alzheimer’s drug on efficacy groundsBiogen and Eisai have announced they are discontinuing two Phase III trials, Engage and Emerge, evaluating the safety and efficacy of aducanumab in patients with Alzheimer’s disease and mild Alzheime2019/3/25
-
Novo Nordisk, aiming for approval this fall, puts first-ever oral GLP-1 drug up for FDA reviewNovo Nordisk has big hopes for its new oral version of GLP-1 diabetes drugsemaglutide, and on Wednesday, it took onestep closer to turning those hopes into reality. Novo officiallysubmittedan applica2019/3/22
-
Puma Biotech to pay PPD founder $22M in defamation suit from proxy fightYears ago, Puma Biotechnology beat PPD founder and ex-CEO Fred Eshelman’s attempt to grab more control over its board. But thanks to a Tuesday jury verdict, the biotech now owes Eshelman $22.3 millio2019/3/22
-
C2 Pharma doubles down on supplies of digoxin APIC2 Pharma, which concentrates on hard-to-make ingredients, has picked up a new supply of digoxin. The deal will give it two supplies of API for making the sometimes difficult-to-get drug. The Luxembo2019/3/21
-
Merck KGaA investing €1B at headquarters site as part of 5-year work agreementMerck KGaA’s headquarters site in Darmstadt, Germany, is the pride of its international operations, and it intends to keep it that way. The German drug and materials maker says it has nailed down new2019/3/21
-
Lilly's $7M tax abatement in Indianapolis draws bipartisan pushback: reportsEli Lilly rolled out an $850 million investment plan for the U.S. two years ago, with a chunk of that earmarked for its hometown. But one of those Indianapolis building projects is getting some pushb2019/3/20
-
Novo's Victoza won't face Teva copies until 2023. Can semaglutide fill the gap by then?Novo Nordisk has at least four more years to build up its newer diabetes drugs before they'll have to compete with Teva's knockoff versions of its own blockbuster Victoza. Under a new patentsettlemen2019/3/20
-
NASA calls for new vaccinations to combat virus reactivation during spaceflightResearchers from NASA’s Johnson Space Center have discovered that dormant herpes viruses reactivate during spaceflight, leading to an urgent need to develop counter-measures, including vaccination, t2019/3/19
-
Blackstone to acquire anti-rheumatism drugs maker Ayumi PharmaceuticalBlackstone’s private equity funds have signed a definitive agreement to acquire Japan-based anti-rheumatism drugs manufacturer Ayumi Pharmaceutical from Unison Capital and M3. Ayumi was established i2019/3/19
-
EC approves Merck’s Keytruda for metastatic squamous NSCLCThe European Commission (EC) has approved Merck’s anti-PD-1 therapy Keytruda as a first-line treatment for adults with metastatic squamous non-small cell lung cancer (NSCLC). The indication covers th2019/3/18